$MRVI, Maravai LifeSciences, has announced a delay in its Q4 earnings report and will file a Form 12b-25 with the U.S. Securities and Exchange Commission, indicating a late filing for its annual report on Form 10-K for the fiscal year ending December 31, 2024. The company's stock has seen a decline of 12.7% in the afternoon trading session, contributing to a year-to-date drop of 27%. Some market observers have expressed skepticism regarding the management's ability to navigate this situation, with one noting a 95% drawdown for the stock. The current market sentiment reflects a transition for growth investors, as they are increasingly viewed as deep value investors amid these developments.